DAX25.351 -0,2%Est506.014 ±-0,0%MSCI World4.343 -0,1%Top 10 Crypto12,33 +1,3%Nas23.734 +0,3%Bitcoin78.991 +1,1%Euro1,1666 ±-0,0%Öl64,74 +0,7%Gold4.586 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 Deutsche Telekom 555750 DroneShield A2DMAA RENK RENK73 Siemens Energy ENER6Y Lufthansa 823212 Allianz 840400 Infineon 623100 Amazon 906866 BASF BASF11 Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schwächelt -- Asiens Börsen letztlich uneins - Nikkei knackt Rekord -- EZB-Ausblick: Zinserhöhung unwahrscheinlich -- Rüstungsaktien, DEUTZ, Zalando, Munich Re, DroneShield, Nordex im Fokus
Top News
Intel: Apple soll laut KeyBanc-Analysten ein Kunde bei 18A sein und bei 14A werden! Intel: Apple soll laut KeyBanc-Analysten ein Kunde bei 18A sein und bei 14A werden!
DroneShield erweitert Aktienkapital: Ausgabe neuer Wertpapiere nach Optionsausübung DroneShield erweitert Aktienkapital: Ausgabe neuer Wertpapiere nach Optionsausübung
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Verteidigung als Anlagechance: Mit diesem ETF erhältst du Zugang zu europäischen Unternehmen aus dem Luft-, Raumfahrt- und Verteidigungssektor

Carlisle Companies Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
301,10 EUR -5,30 EUR -1,73 %
STU
356,43 USD +1,21 USD +0,34 %
BTT
Carlisle Companies jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.12,72 Mrd. EUR

KGV20,32Div. Rendite1,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN871884

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS1423391002

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCSL

Carlisle Companies Aktien News

DatumMeistgelesen
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireJapan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan b...
PR NewswireCSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
PR NewswireCSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
PR NewswireCSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
PR NewswireNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
PR NewswireRecently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireFerinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
PR NewswireCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireHalf year reported NPATA US$2 billion¹,² Up 13% at constant currency³
PR NewswireCSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
PR NewswireNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
PR NewswireHarris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
PR NewswireSwissmedic erteilt Zulassung für CSLs HEMGENIX® (Etranacogene Dezaparvovec) als erste Gentherapie für Hämophilie B
PR NewswireCSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
PR NewswireCSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
PR NewswireCSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
PR NewswireCSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in Peopl...
PR NewswireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
PR NewswireCSL and uniQure Win 2023 Prix Galien USA Award

Carlisle Companies News

Carlisle Companies News: auf dieser Seite finden Sie alle Carlisle Companies News und Nachrichten zur Carlisle Companies Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Carlisle Companies News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Carlisle Companies News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.